Bispecific Antibody Hematology Deal Benchmarks

Bispecific antibodies have emerged as a major competitive force in hematologic oncology, challenging CAR-T cell therapy with off-the-shelf convenience and lower manufacturing complexity. Phase 2 bispecific hematology deals carry a median total deal value of $3.6B, with upfront payments of $717M. Approved agents like glofitamab, epcoritamab, and teclistamab have validated the bispecific approach across lymphoma and myeloma.

Deal structures for hematology bispecifics reflect the rapid clinical development timelines and accelerated approval pathways. Development milestones average $601M, regulatory milestones contribute $716M, and commercial milestones reach $1.5B. The overall 20/80 upfront/milestone split reflects moderate clinical risk at Phase 2.

Royalty rates for hematology bispecific deals range from 9% to 16.9%, with escalation to 20.9% on peak sales. Key differentiation factors include subcutaneous versus intravenous formulation, step-up dosing requirements, cytokine release syndrome profile, and activity in CAR-T-refractory patients. Fixed-duration therapy bispecifics command premium terms over continuous treatment approaches.